Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.50 |
| ▸ | KRAS | P01116 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1506529 | 0.86 | NT5E (0.56) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL16555277 | 0.84 | HINT1 (0.55) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL16496063 | 0.83 | TGM2 (0.54) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL1120568 | 0.82 | HINT1 (0.59) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL20870831 | 0.82 | HPGD (0.60) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL24299397 | 0.82 | HINT1 (0.62) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL13833323 | 0.82 | HINT1 (0.62) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL16114092 | 0.82 | HINT1 (0.62) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL4278130 | 0.82 | HINT1 (0.62) | HINT1NT5ESTING1PDE3BPDE3A | |
| SCHEMBL2510562 | 0.82 | HINT1 (0.62) | HINT1NT5ESTING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038853-A1 | USHER SYNDROME-RELATED GENE MODIFICATION | AMBER BIO INC. (US) | 2025-02-20 | — | — | WO | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| EP-4306643-A2 | PLASMID CONTAINING A SEQUENCE ENCODING AN MRNA WITH A SEGMENTED POLY(A) TAIL | ethris GmbH (DE) | 2024-01-17 | — | — | EP | claimed |
| EP-1027432-A2 | RIBOZYMES TARGETED TO IL-15 mRNA | Hisamitsu Pharmaceutical Co., Inc. (JP) | 2000-08-16 | — | — | EP | claimed |
| US-6087172-A | FOR TREATMENT OF RHEUMATOID ARTHRITIS BY SUPPRESSION OF INTERLEUKIN-15 PRODUCTION | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2000-07-11 | — | — | US | claimed |
| EP-0948513-A1 | DELIVERY CONSTRUCT FOR ANTISENSE NUCLEIC ACIDS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1999-10-13 | — | — | EP | claimed |
| US-5942395-A | A RECOMBINANT RNA HAVING A HAMMERHEAD OR HAIRPIN RIBOZYME CATALYTIC SEQUENCE AND A SMALL NUCLEOLAR RNA STABILIZING MOTIF; ANTICARCINOGENIC/ANTITUMOR/ANTIPROTOZOA AGENTS, TREATMENT OF HIV, AUTOIMMUNE AND CARDIOVASCULAR DISEASES | UNIVERSITE DE MONTREAL (CA) | 1999-08-24 | — | — | US | claimed |
| WO-1999023208-A2 | RIBOZYMES TARGETED TO IL-15 mRNA | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1999-05-14 | — | — | WO | claimed |
| WO-1998050408-A1 | HYBRID RIBOZYMES AND METHODS OF USE | UNIVERSITY OF MASSACHUSETTS (US) | 1998-11-12 | — | — | WO | claimed |
| US-5814500-A | FOR SUPPRESSING EXPRESSION OF A TARGET GENE | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1998-09-29 | — | — | US | claimed |
| WO-1998018811-A1 | DELIVERY CONSTRUCT FOR ANTISENSE NUCLEIC ACIDS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1998-05-07 | — | — | WO | claimed |
| CN-113396219-B | Purification of mRNA by tangential flow filtration | ETHRIS GMBH (DE) | 2026-05-26 | — | — | CN | disclosed |
| EP-4717779-A2 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TriLink BioTechnologies, LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4276189-B1 | INITIATING CAPPED OLIGONUCLEOTIDE PRIMERS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| CN-121586722-A | Compositions and methods for generating immunity to bacterial infections | 辛泰伦有限责任公司 | 2026-02-27 | — | — | CN | disclosed |
| WO-1998045450-A1 | PURIFIED TELOMERASE | GERON CORPORATION (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5814500-A | FOR SUPPRESSING EXPRESSION OF A TARGET GENE | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1998-09-29 | — | — | US | disclosed |
| WO-1998039661-A1 | METHOD FOR IDENTIFYING HORMONALLY MODULATED GENES | DIAGNOSTIC PRODUCTS CORPORATION (US) | 1998-09-11 | — | — | WO | disclosed |
| WO-1998018811-A1 | DELIVERY CONSTRUCT FOR ANTISENSE NUCLEIC ACIDS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0311694-A1 | NUCLEOSIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | RIKAGAKU KENKYUSHO (JP) | 1989-04-19 | — | — | EP | disclosed |